Researchers suggest risk of cervical or vaginal cancer higher in women previously treated for pre-cancerous cells on cervix

January 14, 2014

Women previously treated for abnormal cells on the cervix (CIN3 or cervical intraepithelial neoplasia grade 3) are at an increased risk of developing and dying from cervical or vaginal cancer compared with the general female population and this risk accelerates above age 60, a paper published today on suggests.

Cytology screening to prevent cervical cancer is a medical success story and examinations have proven to be an effective way to reduce deaths from cervical cancer. However, the risk of cervical cancer is not eliminated when abnormal cells are detected and removed and as such women are asked to participate in follow-up programmes.

No prior study has investigated how ageing affects the risk of death from cervical cancer after treatment of CIN3. Researchers from Sahlgrenska University Hospital and Karolinska Institute in Sweden therefore aimed to investigate how age affected this risk.

They used data from the Swedish Cancer Registry which contained information on 150,883 women with CIN3, 1,089 of which had a diagnosis of invasive cervical cancer and 147 women who had a diagnosis of vaginal cancer. 302 and 53, respectively, had died of these diseases.

The researchers found there was an increased risk of invasive cervical and invasive vaginal cancer as women once treated for CIN3 grew older. The risk, compared to the general female population, accelerated after the age of 60. After the age of 75, incidence rates increased further with rates exceeding 100 per 100,000 women over this age. Also, the more recently a woman had been treated, the higher the risk of cancer.

There was also an increase in excess risk with age at treatment of CIN3: after adjusting for duration of follow-up and treatment period there was a fivefold increase in risk for treatment at age 60-69 compared with women aged 30-39.

The study covered a total of 3,160,978 women-years and found that there were 355 cause-specific deaths during the study period. There was a steep increase in risk of death with increased age after previous diagnosis of CIN3. This risk was more than doubled after 30 years following treatment, compared with the general population. In women of 72 years of age, death rates has accelerated to 50 per 100,000 women. Death rates also increased with age at treatment.

The researchers do, however, want to reassure patients that "after treatment for CIN3 [...] they are well protected from cervical cancer". They say only a minority of those treated will develop cancer and die from the disease and add that women treated have not only been screened and treated, "but can also be assumed to have been followed up more closely (at least for a time) than other women of the same age" and are easily identifiable.

The researchers conclude that the treatment for CIN3 is very beneficial for women with this diagnosis. However the risk of developing cervical or vaginal cancer and of dying from one of these cancers among women previously treated for CIN3 is strongly increased after the age of 60 and 70 respectively, compared to the general female population. They also found that treatment later in life increased this risk and recommend that women "previously treated for CIN3 should be followed up in old age".

In an accompanying editorial, Dr Arbyn from the Unit of Cancer Epidemiology in Brussels says we need to find out why cervical cancer risk increases with age and looks worse for women treated more recently. He says that precancerous lesions which are not clearly visible at colposcopy are more common in older than younger women and that "age-specific immunity may contribute to the ultimate cure of cervical precancer".

He says it is worrying that the study found that women who received treatment more recently were at greater risk of developing cervical and vaginal cancer and that the use of less aggressive treatments and the decreased use of hysterectomy may explain the increase in cervical cancer after treatment of CIN3 observed in recent years in Sweden.

He concludes that research is needed to identify markers that predict a woman's future risk of cancer and that "measures should be taken to assure full compliance with follow-up after treatment of cervical precancer".
Research: Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population-based cohort study of long term incidence and mortality

Editorial: Long term outcomes for women treated for cervical precancer


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to